Governor Newsom signs legislation creating non-UPF label, other health bills advancing California’s nation-leading healthcare strategy - California State Portal | CA.gov

What you need to know: First Partner Jennifer Siebel Newsom and Chancellor Marcelo Suárez-Orozco, in patronage of the Pontifical Academy of Social Sciences, convened global scientists, academicians, doctors, faith leaders, state officials, and advocates for a two-day summit exploring opportunities to advance social connection and belonging in a time of uncertainty and division. VATICAN CITY – First Partner Jennifer Siebel Newsom and Chancellor Marcelo Suárez-Orozco, in patronage of the Pontifical Academy of Social Sciences (PASS), co-hosted a two-day international summit at the historic Casina Pio IV at the Vatican last week. The summit brought together cross-sector leaders to confront the growing global crisis of social disconnection, advance a shared agenda to treat social health with the same urgency as physical and mental health, and share all of the programs that California and other communities across the world have modeled to answer this call.

Gov. Gavin Newsom this week claimed a major victory for CARE Court, his program to provide mental health treatment to Californians with serious conditions. Did it really help 10,000 people?” Gov. Gavin Newsom claimed a major victory for his signature mental health court on Thursday, but critics say his math appears more than a little fuzzy.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.